Adamas Pharmaceuticals, Inc. (ADMS)
(Delayed Data from NSDQ)
$6.39 USD
+0.11 (1.75%)
Updated May 3, 2019 04:00 PM ET
After-Market: $6.38 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[ADMS]
Reports for Purchase
Showing records 1 - 20 ( 26 total )
Industry: Medical - Generic Drugs
Acquisition by Supernus Announced; Downgrading to Neutral and $9.10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
Industry: Medical - Generic Drugs
Top and Bottom-Line 2Q21 Miss; Solid Expense Control; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
Additional Marketed Product Patent Claims Granted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
Chasing Cash Flow Breakeven; Lowering PT to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
GOCOVRI Label Expansion; Generic Entry Timeline Clarity; Raising PT to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
Patent Litigation Settled; Royalty-Backed Loan Amended; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
Outlook Remains Lukewarm; 3Q20 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
Revenue In-Line, Bottom-Line Beat; 2Q20 Financial Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
GOCOVRI Supplemental New Drug Application Accepted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
1Q20 Financials; Modest Top-Line and Substantial Bottom-Line Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
2019 Financials; Revenue In-Line; Modest Bottom-Line Miss; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
Preliminary 4Q19 Revenue Reported; GOCOVRI Gradually Beating Expectations; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
INROADS Trial Meets Primary Endpoint; Yet Disappoints Overall; Reducing Target to $10
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
INROADS Top-Line Study Data Imminent; 3Q19 Financials; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
Leadership Transition Announced; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
2Q19 Financial Results; Revenue In-Line, Bottom-Line Beat; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
Surveying the Parkinson''s Disease Treatment Continuum: KOL Conference Call Recap
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
Baby Thrown Out With the Bathwater; Attrition Extent Appears Unwarranted; Reiterate Buy; Lowering Target to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Industry: Medical - Generic Drugs
FY2018 Financial Results Reported; 2019 Revenue Guidance Suspended; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R